Skip to main content

beta This is a new site, your feedback will help us to improve it.

FOI release

FOI – 000098 Volume of coagulation factor distributed to NHS Scotland Hospitals from Jan '22 to Mar '22 (HTML)

Published on 24 May 2022

Date received – 26 April 2022: Date responded – 24 May 2022

Request

I would like to submit an FOI request for the volume of coagulation factor (in IU or mg) distributed to NHS Scotland Hospitals in each month from January 2022 to March 2022, broken down by-product (see below). If the volume by brand is not available, I would like to request the number of vials distributed by brand. If possible, I would also like the number of patients by brand. Thank you very much for your time and assistance:

  • Hemlibra
  • Esperoct
  • Adynovi
  • Elocta
  • NovoEight
  • Advate
  • ReFacto AF
  • Nuwiq
  • NovoSeven
  • FEIBA
  • Obizur
  • Idelvion
  • Refixia
  • Alprolix
  • BeneFIX
  • Replenine
  • Rixubis

Response

I can advise you that we have now completed the search of our records and can provide you with the following information:

Usage data is presented in Appendix 1, which is for NHS Scotland secondary care (hospital and homecare usage) detailing the volume of coagulation factor distributed to NHS Scotland, please see below a few points to consider when reviewing the data:

  • Usage data on the spreadsheet has been separated into secondary care usage and homecare usage. Patients in the first instance are treated in the acute centre and, when stable on their prescribed medication, can get a hospital prescription delivered to their home. The homecare medicine delivery service delivers ongoing medicine supplies and, where necessary, associated care, initiated by the hospital prescriber, direct to the patient’s home with their consent.
  • The Commercial Medicines Unit (CMU) in NHS England facilitate the allocation of supply to secondary care in NHS Scotland. Hospital usage is not broken down by patient specific prescriptions, therefore, patient numbers are not known. However, patient numbers treated within homecare have been included (by brand).
  • The volume by brand has been provided for both care settings.
  • There is no usage data for a number of brands detailed in the request as there are no patients on these medicines within NHS Scotland.

I trust you will find the information of assistance and if you require any further information please do not hesitate to contact us.

If you are unhappy with any aspect of how we have dealt with your request, you can make representations to us asking us to review the handling of your request. Please get in touch with us using the below contact details within 40 working days of the date of this correspondence:

NHS National Services Scotland
Headquarters
Gyle Square
1 South Gyle Crescent
Edinburgh
EH12 9EB

Email: nss.foi@nhs.scot

If after a review you are still unhappy, you also have the right to apply to the Scottish Information Commissioner, who can be contacted at Kinburn Castle, St Andrews, Fife, KY16 9DS, or via their online application form.

If you have any queries about this letter, please contact us at the above address.